Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates

被引：13
作者：
Yokota, Shin-ichi [1 ]
Ohkoshi, Yasuo [1 ]
Fujii, Nobuhiro [1 ]
机构：
[1] Sapporo Med Univ, Sch Med, Dept Microbiol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2009年 / 65卷 / 01期
关键词：
Streptococcus pneumoniae; Quinolones; Antibiotic resistance; PK/PD; Respiratory tract infection; RESPIRATORY-TRACT INFECTIONS; IN-VITRO; GARENOXACIN BMS-284756; PHARMACODYNAMICS; DES-F(6)-QUINOLONE; STRAINS;
D O I：
10.1016/j.diagmicrobio.2009.05.006
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
We evaluated the pharmacokinetic/pharmacodynamic parameters of 8 oral quinolones (ciprofloxacin, garenoxacin [GRNX], gatifloxacin, levofloxacin, moxifloxacin, prulifloxacin, sitafloxacin, and sparfloxacin) on 11 fluoroquinolone-resistant Streptococcus pneumoniae strains, screened from 780 strains isolated from various clinical sources in Japan. GRNX showed the highest area under the blood concentration time curve/MIC ratios, which exceeded the target values for bacterial eradication against all fluoroquinolone-resistant S. pneumoniae strains. (C) 2009 Elsevier Inc. All rights reserved,
引用
收藏
页码：76 / 80
页数：5
相关论文
共 16 条
[1]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[2]   Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae [J].
Blondeau, JM ;
Zhao, XL ;
Hansen, G ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :433-438
[3]   Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae:: data from the global PROTEKT surveillance programme [J].
Canton, R ;
Morosini, M ;
Enright, MC ;
Morrissey, I .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (06) :944-952
[4]  
*CLIN LAB STAND I, 2006, M077 CLSI
[5]   Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756 [J].
Fung-Tomc, JC ;
Minassian, B ;
Kolek, B ;
Huczko, E ;
Aleksunes, L ;
Stickle, T ;
Washo, T ;
Gradelski, E ;
Valera, L ;
Bonner, DP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3351-3356
[6]   In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones [J].
Grohs, P ;
Houssaye, S ;
Aubert, A ;
Gutmann, L ;
Varon, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3542-3547
[7]   Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values [J].
Jones, Ronald N. ;
Fritsche, Thomas R. ;
Sader, Helio S. ;
Stilwell, Matthew G. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2007, 58 (01) :9-17
[8]   Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones [J].
Lister, PD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) :199-201
[9]   In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae [J].
Madaras-Kelly, KJ ;
Demasters, TA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 37 (04) :253-260
[10]   Fluoroquinolone-resistant Streptococcus pneumoniae in Spain:: Activities of garenoxacin against clinical isolates including strains with altered topoisomerases [J].
Morosini, MI ;
Loza, E ;
del Campo, R ;
Almaraz, F ;
Baquero, F ;
Cantón, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2692-2695
12